Market open
Anavex/$AVXL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anavex
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Ticker
$AVXL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
42
ISIN
US0327973006
Website
Anavex Metrics
BasicAdvanced
$697M
-
-$0.56
0.82
-
Price and volume
Market cap
$697M
Beta
0.82
52-week high
$14.44
52-week low
$3.51
Average daily volume
910K
Financial strength
Current ratio
6.739
Quick ratio
6.699
Management effectiveness
Return on assets (TTM)
-25.44%
Return on equity (TTM)
-40.17%
Valuation
Price to book
6.99
Price to tangible book (TTM)
6.99
Price to free cash flow (TTM)
-23.239
Growth
Earnings per share change (TTM)
12.09%
3-year earnings per share growth (CAGR)
-1.34%
What the Analysts think about Anavex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Anavex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Anavex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Anavex News
AllArticlesVideos
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
GlobeNewsWire·1 day ago
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $697M as of May 15, 2025.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of May 15, 2025.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.